BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism.Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been a

TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275416). The offering is expected to close on or about

Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC:PINKPXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense st

TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the "Company" or "PaxMedica") (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica's recent achievements and ongoing actions to regain compliance

TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company's commitment to advancing treatments for neurological disorders. Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for  anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)." The com

LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica (NASDAQ:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, takes center stage in the episode. During this insightful conversation, Howard Weisman, CEO of PaxMedica, and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of Health, joined host Stuart Smith to di

TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (NASDAQ:PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east Africa. The request seeks emergency access to the Company's recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region. How

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drug TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to I

TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), which is currently planned for Q4 2024, and for the potential commercial availability in the U.S. of the first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei rhod

TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica's strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community. Click here to view the presentation. The new presentation, available on the PaxMedica website, outlines the company's focused pipeline, including its leading investigational drug, PAX-101. With its approach to targeting the core symptoms of ASD, PaxMedica is l

8-K - PaxMedica, Inc. (0001811623) (Filer)

NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)

EFFECT - PaxMedica, Inc. (0001811623) (Filer)

S-1 - PaxMedica, Inc. (0001811623) (Filer)

10-Q - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

4 - PaxMedica, Inc. (0001811623) (Issuer)

TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ:PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease. The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African Sleeping Sickness cause

Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced the return of David Hough, M.D., as Chief Medical Officer (CMO) of PaxMedica, effective immediately.  Dr. Hough  has been a key consultant to the company during 2023 and was the company's CMO from 2020-2022. He is board-certified in both adult and geriatric psy

-PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022- -Phase 3 Results for HAT-301 Trial Expected in First Half 2023- TARRYTOWN, NY, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022. Howard Weisman, Chief Executive Officer of PaxMedica, commented, "The third quarter was PaxMedica's first as a publ

Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry  TARRYTOWN, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disorder ("ASD"), today announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer.  In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica's pipeli

Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Director  TARRYTOWN, NY, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disease ("ASD"), today announced the appointment of Charles (Chuck) J. Casamento to the company's Board of Directors. Mr. Casamento's appointment was effective as of October 1, 2022. "We are honored and excited to welcome Chuck to the Board of PaxMed

SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

SC 13G - PaxMedica, Inc. (0001811623) (Subject)

SC 13D - PaxMedica, Inc. (0001811623) (Subject)

SC 13G - PaxMedica, Inc. (0001811623) (Subject)